Physician profile
Robert E Bloom
NPI 1760413389
$7,173.19
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $4,464 · 2021: $844 · 2022: $525 · 2023: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $108.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $4,514.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $825.00 | 2021 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $249.84 | 2019 | |
| Genentech USA, INC. | $179.72 | 2019-2020 | |
| Kite Pharma, INC. | $124.89 | 2019 | |
| Seagen INC. | $108.43 | 2023 | Adcetris |
| Merck Sharp & Dohme LLC | $75.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $66.51 | 2019 | |
| Amgen INC. | $56.97 | 2019 | |
| Alexion Pharmaceuticals, INC. | $45.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $42.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.99 | 2019 | |
| Allergan, INC. | $32.91 | 2019 | |
| Gilead Sciences, INC. | $30.62 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $30.03 | 2019 | |
| Dynavax Technologies Corporation | $27.44 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.65 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $24.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2019 | |
| Emd Serono, INC. | $22.44 | 2019 | |
| Celgene Corporation | $20.14 | 2019 | |
| Melinta Therapeutics, LLC | $17.71 | 2019 | |
| Clovis Oncology, INC. | $16.06 | 2019 | |
| Exelixis INC. | $15.77 | 2019 | |
| Vyera Pharmaceuticals, LLC | $14.68 | 2019 | |
| Pfizer INC. | $12.67 | 2019 | |
| Tersera Therapeutics LLC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.